Primary Outcome Measures
- Incidence of Adverse Events (AEs) [ Time Frame: Up to 6 Months ]
- Time to onset of serious adverse events (SAEs) [ Time Frame: Up to 6 Months ]
- Time to onset of AEs [ Time Frame: Up to 6 Months ]
- Time to resolution of AEs [ Time Frame: Up to 6 Months ]
- Time to resolution of SAEs [ Time Frame: Up to 6 Months ]
- Incidence of physician seriousness assessment measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade – Non-serious AE [ Time Frame: Up to 6 Months ]
- Incidence of physician seriousness assessment measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade – SAE [ Time Frame: Up to 6 Months ]
- Incidence of AEs leading to interruption of treatment [ Time Frame: Up to 6 Months ]
- Incidence of SAEs leading to interruption of treatment [ Time Frame: Up to 6 Months ]
- Incidence of AEs leading to treatment discontinuation [ Time Frame: Up to 6 Months ]
- Incidence of SAEs leading to treatment discontinuation [ Time Frame: Up to 6 Months ]
- Outcome of reported AEs [ Time Frame: Up to 6 Months ]
- Outcome of reported SAEs [ Time Frame: Up to 6 Months ]
- Number of participants with Yervoy and Opdivo treatment related adverse events as assessed by physician causality [ Time Frame: Up to 6 Months ]
- Number of participants with Yervoy and Opdivo treatment unrelated adverse events as assessed by physician causality [ Time Frame: Up to 6 Months ]
Inclusion Criteria
- Initiated treatment with Yervoy and Opdivo in combination for the first time in accordance with the Japanese package insert
Exclusion Criteria
- Received combination therapy with Yervoy and Opdivo for indications other than Malignant Pleural Mesothelioma (MPM).
- Received the Yervoy and Opdivo combination for MPM, but for an indication that is outside of the Japanese package insert.
